Latest Period
Q1 2026
Security Snapshot
Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) Institutional Ownership
CUSIP: 92840H400
13F Institutional Holders and Ownership History from Q2 2023 to Q2 2026
Institutions Reporting
53
Shares (Excl. Options)
14,115,301
Price
$0.57
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- VTGN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 14,115,301
- Total 13F value
- $8,065,740
- Portfolio coverage rank
- 0%
- Share change
- +1,015,209
- Value change
- +$509,221
- Number of holders
- 53
- Shares outstanding
- 41,041,331
- SEC-reported price per share
- $0.23
- Insider filing price
- $0.23
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 92840H400.
- 53 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 53 to 1 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $8,065,740 to $3,390.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 53 institutions filings for Q1 2026.
Security key
92840H400
Latest holder period
Q1 2026
13F holders
53
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
VTGN full holder history
Vistagen Therapeutics, Inc. SEC filings
Vistagen Therapeutics, Inc. company facts
Vistagen Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92840H400:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
VTGN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $3,243,796 | 4,383,508 | Commodore Capital LP | 31 Dec 2025 | |||
| TCG Crossover GP II, LLC | 10% | $2,343,167 | 4,100,029 | Chen Yu | 31 Mar 2026 | |||
| BIOTECHNOLOGY VALUE FUND L P | 10% | $7,217,318 | 3,084,324 | BVF PARTNERS L P/IL | 31 Dec 2024 | |||
| GREAT POINT PARTNERS LLC | 5% | -22% | $1,521,317 | 2,055,834 | 0% | Great Point Partners, LLC | 31 Dec 2025 | |
| Nantahala Capital Management, LLC | 4.7% | -53% | $1,445,253 | -$912,064 | 1,953,045 | -39% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| VANGUARD GROUP INC | 4.6% | -15% | $1,240,822 | +$93,162 | 1,824,738 | +8.1% | The Vanguard Group | 31 Dec 2025 |
| ORBIMED ADVISORS LLC | 4.2% | -23% | $1,213,378 | 1,639,700 | 0% | ORBIMED CAPITAL LLC | 31 Dec 2025 | |
| STEMPOINT CAPITAL LP | 1.5% | -84% | $456,394 | -$1,266,690 | 616,749 | -74% | StemPoint Capital LP | 31 Dec 2025 |
As of 31 Mar 2026, 53 institutional investors reported holding 14,115,301 shares of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN). This represents 34% of the company’s total 41,041,331 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
33%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7.5% | 3,060,000 | 0% | 0.04% | $1,748,790 |
| TCG Crossover Management, LLC | 6.5% | 2,676,580 | 0% | 0.04% | $1,529,665 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 1,574,200 | 0% | 0% | $900,442 |
| ADAR1 Capital Management, LLC | 1.8% | 751,141 | +20% | 0.03% | $429,277 |
| ACADIAN ASSET MANAGEMENT LLC | 1.4% | 589,663 | 0% | $336,000 | |
| Ikarian Capital, LLC | 1.3% | 519,077 | 0% | 0.04% | $296,654 |
| TWO SIGMA INVESTMENTS, LP | 1.1% | 469,619 | +140% | 0% | $268,387 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 453,391 | +28% | 0% | $259,170 |
| BlackRock, Inc. | 1.1% | 448,507 | +6.1% | 0% | $256,322 |
| MILLENNIUM MANAGEMENT LLC | 1% | 430,404 | +118% | 0% | $245,976 |
| LUMINUS MANAGEMENT LLC | 0.97% | 396,053 | +13% | 0.14% | $226,344 |
| RENAISSANCE TECHNOLOGIES LLC | 0.71% | 291,300 | +81% | 0% | $166,478 |
| AdvisorShares Investments LLC | 0.68% | 277,110 | +11% | 0.03% | $158,368 |
| JANE STREET GROUP, LLC | 0.66% | 272,811 | -48% | 0% | $155,912 |
| VANGUARD FIDUCIARY TRUST CO | 0.53% | 217,700 | 0% | 0% | $124,524 |
| Verdad Advisers, LP | 0.45% | 184,938 | 0.12% | $105,692 | |
| XTX Topco Ltd | 0.37% | 152,849 | 0% | $87,353 | |
| Shay Capital LLC | 0.35% | 144,452 | 0.01% | $82,554 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.35% | 142,607 | -57% | 0% | $81,500 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.33% | 134,571 | 0% | 0% | $76,907 |
| STATE STREET CORP | 0.3% | 121,114 | 0% | 0% | $69,217 |
| TUDOR INVESTMENT CORP ET AL | 0.26% | 106,172 | +39% | 0% | $60,677 |
| DIADEMA PARTNERS LP | 0.26% | 105,428 | +5.4% | 0.03% | $60,252 |
| SIMPLEX TRADING, LLC | 0.22% | 89,649 | 0% | $51,279 | |
| UBS Group AG | 0.19% | 78,736 | +51% | 0% | $45,037 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q1 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 15,000 | $3,390 | +$3,390 | $0.23 | 1 |
| 2026 Q1 | 14,115,301 | $8,065,740 | +$509,221 | $0.57 | 53 |
| 2025 Q4 | 13,134,779 | $8,693,359 | -$30,764,910 | $0.66 | 53 |
| 2025 Q3 | 23,364,193 | $81,815,600 | +$30,638,552 | $3.55 | 58 |
| 2025 Q2 | 14,875,235 | $29,750,933 | -$917,939 | $2.00 | 50 |
| 2025 Q1 | 15,325,061 | $38,287,272 | +$856,836 | $2.50 | 47 |
| 2024 Q4 | 14,903,856 | $43,958,204 | -$1,103,443 | $2.95 | 54 |
| 2024 Q3 | 14,643,797 | $44,079,533 | +$4,636,495 | $3.01 | 47 |
| 2024 Q2 | 13,044,677 | $45,399,902 | -$5,789,213 | $3.48 | 42 |
| 2024 Q1 | 14,613,555 | $76,690,483 | -$1,575,877 | $5.28 | 41 |
| 2023 Q4 | 14,910,095 | $76,226,105 | +$50,694,989 | $5.14 | 45 |
| 2023 Q3 | 3,003,814 | $15,739,243 | +$10,117,983 | $5.24 | 34 |
| 2023 Q2 | 966,706 | $1,807,113 | +$1,807,113 | $1.87 | 30 |